Doxorubicin Liposomal manufacturers & suppliers

Doxorubicin Liposomal

Form: Liposomal Injection (

Strength: 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL)

Reference Brands: Doxil® , Caelyx® (EU & US)

Category: Oncology Cancer Care

Doxorubicin Liposomal, marketed as Doxil® (US) and Caelyx® (EU), is a chemotherapy agent used to treat breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. Its liposomal formulation encapsulates the doxorubicin drug, allowing for more targeted delivery and reduced systemic toxicity compared to conventional doxorubicin. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is supplied in single-use vials for oncology treatment. Sourced from GMP-compliant manufacturers, Doxorubicin Liposomal offers effective treatment for cancer patients while minimizing side effects, making it a trusted choice for healthcare providers in US and EU markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Vimseltinib

Strength: 14 mg; 20 mg; 30 mg

Form: Capsules

Reference Brands: Romvimza

View Details
Atezolizumab

Strength: 1200 mg/20 mL

Form: Intravenous infusion

Reference Brands: Tecentriq® (EU & US)

View Details
Durvalumab

Strength: 120 mg/4 mL, 500 mg/10 mL

Form: Injection

Reference Brands: Imfinzi® (US & EU)

View Details
Sunitinib

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Form: Tablet

Reference Brands: Sutent® (EU & US)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.